|
Telisotuzumab Adizutecan Clinical Trials
8 actively recruiting trials across 5 locations
Also known as: ABBV-400
Pipeline
Phase 2: 3Phase 3: 1Phase 1/2: 2Phase 2/3: 2
Top Sponsors
- AbbVie8
Indications
- Cancer8
- Lung Cancer3
- Colorectal Cancer2
- Metastatic Colorectal Cancer2
- Solid Tumors Harboring MET Amplification1
Duarte, California3 trials
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
City of Hope National Medical Center /ID# 267875
Phase 3
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
City of Hope National Medical Center /ID# 275613
Phase 2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
City of Hope National Medical Center /ID# 270255
Phase 2
Other1 trial
Huntsville, Alabama1 trial
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Clearview Cancer Institute - Huntsville - Cci Drive /ID# 278621
Phase 2
Springdale, Arkansas1 trial
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Highlands Oncology Group - Springdale /ID# 277132
Phase 2/3
Fullerton, California1 trial
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Providence - St. Jude Medical Center /ID# 271414
Phase 1/2
Los Angeles, California1 trial
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
USC Norris Comprehensive Cancer Center /ID# 275343
Phase 2/3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.